Viatris agreed to buy Pacira as UBS raised target for Viatris stock to USD 26.00

Published on 10/15/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pacira generated USD 746 million in revenue in the last twelve months. Viatris stock was at EUR 15.67 on October 15, 2026, with UBS targeting USD 26.00.

Acquisition and analyst outlook

Viatris agreed to acquire Pacira for USD 1.65 billion on October 8, 2026.
Pacira generated USD 746 million in revenue during the twelve months ended June 30, 2026.
Viatris stock was trading at EUR 15.67 at 1:10 p.m. CEST on October 15, 2026, at Lang & Schwarz.

Architekturvisualisierung eines generischen modernen Filmstudio-Backlot mit großen Hallenbauten — Paramount Global (US92556V1061) Architektur-Render zeigt modernen generischen Filmstudio-Backlot-Komplex im minimalistischen Baustil klar, Illustration mit AI erstellt.

Viatris (ISIN US92556V1061) agreed to acquire Pacira BioSciences for USD 1.65 billion on October 8, 2026, while UBS had raised its price target for Viatris to USD 26.00 from USD 23.00 on October 5, 2026. The deal adds marketed pain medicines as the company expands its innovative medicines strategy.

Pacira adds USD 746 million revenue

According to Pacira BioSciences, Pacira generated USD 746 million in total revenue and USD 177 million in adjusted EBITDA during the twelve months ended June 30, 2026. Viatris will pay USD 36.50 per Pacira share in cash, and the transaction is expected to close by the end of 2026.

The release says Pacira brings EXPAREL and ZILRETTA, two patent-protected U.S. medicines, together with commercial, market-access, medical-affairs and research capabilities. Viatris said the acquisition should be immediately accretive to its financial guidance metrics and funded mainly from excess cash.

Three dated steps shaped the story

On August 6, 2026, Viatris reported adjusted earnings of USD 0.69 per share and revenue of USD 3.76 billion for the second quarter, according to Investing.com. On October 5, 2026, the company scheduled its third-quarter results for November 5, 2026. On October 8, 2026, Viatris announced the Pacira agreement for USD 1.65 billion.

What does Pacira add?

The transaction gives Viatris exposure to non-opioid pain treatments while Pacira's reported USD 177 million adjusted EBITDA provides a quantified operating base. UBS cited cenerimod, operations in China, hormone replacement therapy and fast-acting meloxicam when it lifted the target to USD 26.00 on October 5, 2026.

The next reporting date is set

Viatris will report third-quarter 2026 results on November 5, 2026, at 8:30 a.m. ET. The call will also cover the Pacira transaction, giving investors the next scheduled update on integration and financial effects.

Stock price and transaction watch

Viatris stock was trading at EUR 15.67 at Lang & Schwarz on October 15, 2026 at 1:10 p.m. CEST. The company had a USD 20.2 billion market capitalization in the October 5, 2026 UBS-linked report, while the analyst target stood at USD 26.00.

The further course of trading is shown by the continuously updated real-time quote of Viatris stock.